Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 7NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Melanoma 14Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Myelodysplastic Syndromes 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Basal Cell 3Burkitt Lymphoma 3Vulvar Neoplasms 2Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Seminoma 2Prostatic Neoplasms 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

montanide ISA 51 3Temozolomide 3Ipilimumab 3Interleukin-2 3sargramostim 2incomplete Freund's adjuvant 2glembatumumab vedotin 2aldesleukin 2Vorinostat 2Sunitinib 2Paclitaxel 2MART-1 Antigen 2Lenalidomide 2Dacarbazine 2Cyclophosphamide 2Carboplatin 2CR011-vcMMAE 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1poly ICLC 1omipalisib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1entinostat 1cixutumumab 1cediranib 1cabozantinib 1aflibercept 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Uveal Melanoma × CTLA-4 Antigen × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡